ICU patients with sepsis suffer from rapidly changing levels of blood glucose concentration which leads to increased mortality, morbidity and length of stay. State of the art for blood glucose control is by discrete blood sampling, manual calculation and dosing of insulin. This is insufficient at controlling the blood glucose concentration for intensive care unit (ICU) patients with sepsis. The solution to this clinical need of the ICU is an affordable automatic glucose control technology: Glycostat. Clinical data exist. Main competitors are Glysure and Marquet. USP: Glycostat does for glucose control what a thermostat does for temperature control. Funding of m€ 6.6 will bring us to CE Mark (21 months) and first sales after 24 months.